Reynolds American Inc. is launching a cigarette that heats tobacco rather than burning it, hoping to capitalize on the growing appetite for alternatives to traditional smokes.
The nation's second-biggest tobacco company said Monday that it will begin selling Revo — a cigarette that uses a carbon tip that heats tobacco after being lit — in Wisconsin in February 2015. Reynolds said the cigarette is a "repositioning" of its Eclipse product first launched in the mid-1990s with minimal success.
The surging e-cigarette or vapor industry has reinvigorated the interest for cigarette alternatives, including products like Revo and its predecessor Eclipse that smokers once considered foreign. Even though the products left no lingering odor and didn't produce ashes, they tasted different than cigarettes and were more difficult to use. Eclipse had remained in limited distribution and is one of the top-selling brands in the cafeteria at Reynolds' headquarters in Winston-Salem, North Carolina.
"Heat-not-burn technology was 20 years ahead of when consumers were ready for it. It needed the mass presence of vapor products to open up an experience-base that smokers understood," said J. Brice O'Brien, head of consumer marketing for the maker of Camel and Pall Mall cigarettes. "The smoker could only compare heat-not-burn to a combustible and it lost every time. That's no longer the case."
Revo is a "modern take on the classic cigarette" that — unlike popular e-cigarettes that use liquid nicotine — contains real tobacco, which could make them more attractive to cigarette smokers, O'Brien said.
Not sure it was the right thing to do, but I bought in the $1's and have a considerable gain. Picked up a shale oil and natural gas company stock that has plummeted, Magnum Hunter Resources.
GLTA ACAD Longs.
The stock price skyrockets at the open to $2.00 a share and trades at $10 with an unprecedented surprise unauthorized 1:5 Reverse Split?
AEterna Zentaris PT Lifted to $6 at Maxim Group
redisnI teertS (Backwards)
Maxim Group analyst Jason Kolbert reiterated a Buy and bumped his price target on AEterna Zentaris (NASDAQ: AEZS) price target of $6.00 (from $5.00) as the company is ready for launch.
Kolbert commented, "AEterna reported $42M in cash with only a modest burn of $9.8M. The company continues its "Resource Optimization Program" with efforts to streamline R&D activities and increase commercial operations and flexibility. The effort to optimize the company as a commercial specialty pharma company is expected to result in 31 employee terminations. Severance packages added $1.6M to this quarter's R&D expense. AEterna also issued 1.6M common shares as part of its May 2014 ATM program, though dilution is minimal, with 59M shares outstanding."
He added, "The co-promotion of Estrogel and Macrilen will begin with AEterna's 20 reps getting out in the field beginning November 17, 2014, which, combined with ASCEND reps, brings the total to 53. This is just in time for the final review of the Macrilen NDA (PDUFA November 5, 2014)."
"Site initiation (120 sites) is now complete for the current ZoptEC (Zoptarelin doxorubicin in endometrial cancer) phase III trials. All sites are operational, and 300 of the expected 500 patients have been enrolled."
Considering that Zogenix stock price was $6 a share in 2011 three years prior to the recent FDA Approval of Zohydro, the company and the product is currently being neglected and the stock price is languishing.
A North Carolina drug maker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.
Chimerix Inc. said Thursday that it has received FDA clearance to proceed with a trial examining the safety and effectiveness of its brincidofovir tablets in patients who have the virus. The company said in a statement that the drug is available for immediate use in testing.
With the FDA's permission, the Durham, North Carolina, drugmaker previously made the drug available to the first Ebola patient diagnosed in the U.S., who died in Dallas last week. Chimerix did not immediately return requests for comment.
The FDA does not publicly confirm when it has granted companies permission to begin testing. The agency has not approved any drugs as safe and effective in treating Ebola.
Brincidofovir is an antiviral drug being developed to treat several types of viruses, including one that infects patients undergoing bone marrow transplants. Chimerix is working with the U.S. Department of Defense on developing the drug as a treatment against smallpox. Laboratory tests suggested it may also work against Ebola.
Chimerix's drug is one of three experimental medications known to have been used on Ebola patients during the current outbreak. The other two are:
ZMapp from San Diego-based Mapp Pharmaceuticals, which was developed specifically as an Ebola treatment. It is a cocktail of antibodies engineered to recognize the virus and bind to infected cells. Supplies are exhausted, though federal officials say work is underway to produce more.
The TKM-Ebola injection, by Tekmira Pharmaceuticals of Canada, works by blocking genes that help the Ebola virus reproduce and spread. It has been used in at least one patient and is said to be in limited supply.
Under pressure to select an Ebola "czar" to lead the U.S. response against the disease, President Barack Obama conceded Thursday it "may be appropriate for me to appoint an additional person" to head the administration effort.
At the time of the article at $4.69 a share that equates to $6.50 a share.
Deval Patrick Says He Might Run for President
Patrick, who's nearing the end of his eight-year run as governor, made the comments in an interview with WCVB.
WCVB reported Patrick made the comments during a taping of its show “ On the Record.”
“There are a lot of people who have asked me to think about (running for president),” Patrick said. “It’s a huge decision, not just for me but for my family.”
When asked if he would indeed run, Patrick said, “Maybe, but not right away.”
Patrick, 58, is nearing the end of his second term as governor. He’s not running for re-election. Massachusetts does not have term limits for the governor’s office.
Patrick is a former civil rights lawyer at the Department of Justice and served as legal counsel for companies like Coca-Cola and Texaco. He has a close relationship with President Obama.
In 2011, Patrick told the State House News Service he’d consider running a company when his run as governor was up.
After he was elected governor in 2006, Patrick said he considered resigning because of the toll the campaign took on his wife, Diane, who was treated for depression.
Before the Reverse Split if a Phase III Approval had taken place, the stock could have possibly jumped from $0.40 a share up into the $1's, $2's or $3's. So stockholders should not be surprised if the price per share in its current valuation was to skyrocket with FDA Approval.